(380v) ZnO Nanoparticles Incorporated MIL-100 for Doxorubicin Delivery

In the present study, an iron based metal organic framework (MOF)
MIL-100 and its composites were synthesised and evaluated
as potential carriers for doxorubicin hydrochloride. An iron based
MOF,  MIL-100 was synthesised at
150 °C using Trimesic acid (BTC) and iron powder. Zinc oxide (ZnO) nanopartcles,
that are bio-friendly and used in pharmaceutical
applications were chosen to prepare MOF composites. At first, ZnO was
prepared by wet chemical method using of Zn ²+  salt under reflux conditions. A series of
composite named ZnO@MIL-100 (Z@M_F) were prepared by adding these ZnO
nanoparticles (in varying mass %) to
the precursor solution of MIL-100. The composite
were characterised by X-ray diffraction, Nitrogen adsorption-desorption
isotherms and Transmission electron microscopy (TEM). 

Doxorubicin hydrochloride (DOX), an anticancer drug used in treatment of
diseases such as leukaemia, lymphoma, and carcinoma was chosen as a model drug. Initially, DOX was loaded
on different MOF composites. The DOX loading was
estimated through analysis of the solution phase by UV-Vis
spectrophotometer. The drug release experiments from these composites
loaded with DOX, were carried out in simulated
phosphate-buffered saline (PBS) solution of pH 7.4 at 37 °C. The highest DOX
loading capacity was found ~21% for Z2@M_F.
The release experiments indicate sustained and release of DOX after
incorporation of ZnO nanoparticles in the MOF structure.

Table : DOX loading details